Core Viewpoint - Zomedica Corp. has expanded its TRUFORMA diagnostic platform to include feline testing capabilities for its cobalamin and folate assay, marking a significant advancement in veterinary diagnostics [1] Group 1: Product Development - The TRUFORMA diagnostic platform now offers a multiplexed assay that combines cobalamin and folate testing, which was previously available only for canine patients [1] - This assay is the first of its kind to provide both cobalamin and folate testing in an in-clinic setting, enhancing the diagnostic capabilities for veterinarians [1] Group 2: Market Position - Zomedica is positioned as an innovative veterinary health company focused on point-of-care diagnostic and therapeutic device products for both equine and companion animals [1]

Company Overview - Zomedica Corp. is a veterinary health company focused on point-of-care diagnostic and therapeutic products for equine and companion animals [3] - The company offers a range of innovative solutions including the PulseVet® shock wave system, Assisi® Loop therapeutic devices, TRUFORMA® diagnostic platform, TRUVIEW® digital cytology system, VETGuardian® monitoring system, and VETIGEL® hemostatic gel [3] - Zomedica's total addressable market in the U.S. exceeds $2 billion [3] - The company is headquartered in Michigan and employs approximately 150 people, with manufacturing and distribution facilities in Georgia and Minnesota [3] Financial Performance - Zomedica reported an 8% revenue growth in 2024, reaching $27 million [3] - As of March 31, 2025, the company maintains a strong balance sheet with approximately $65 million in liquidity [3] Strategic Initiatives - Zomedica is advancing its product offerings through strategic acquisitions and international expansion [3] - The company aims to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow, and profitability of veterinary practices [3] Upcoming Events - Larry Heaton, CEO of Zomedica, will present at the OTCQB Venture Virtual Investor Conference on August 7, 2025, at 1:30 PM ET [1] - The event will allow real-time interaction with investors, and an archived webcast will be available post-event [1]